Feedback
Settings

Settings

Goto Application

428,992 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CTR:MX

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 42,900
1.MX/a/2008/014687PREDICTION OF RELATIVE POLYPEPTIDE SOLUBILITY BY POLYETHYLENE GLYCOL PRECIPITATION
MX - 27.01.2009
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
 Appl.No MX/a/2008/014687 Applicant WYETH.* Inventor NICHOLAS W. WARNE
A method is described for predicting the relative solubility of a polypeptide using polyethylene glycol (PEG) based volume exclusion precipitation. Different polypeptides can be tested for their solubilities relative to each other or relative to a reference. A single polypeptide can be tested for its relative solubility under different experimental conditions. The solubility determinations can be made by comparison based on graphs plotting the log solubility of the polypeptide against a range of PEG concentrations. Additionally, a method is provided for the high throughput visual or automated screening of multiple polypeptides for relative solubility differences, in a method that can omit the step of measuring the actual solubility or actual amount of precipitation of each sample at each PEG concentration.
2.MX/a/2008/014793METHODS OF TREATING STROKE
MX - 12.02.2009
Int.Class A01N 37/18
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
37Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
18containing the group -CO-N, e.g. carboxylic acid amides or imides; Thio-analogues thereof
 Appl.No MX/a/2008/014793 Applicant BIOGEN IDEC MA INC. Inventor JANE K. RELTON
Methods and compositions for treating stroke are disclosed.
3.MX/a/2008/014959COMPOUNDS AND METHODS FOR MODULATING FXR
MX - 12.02.2009
Int.Class A61K 31/4192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41921,2,3-Triazoles
 Appl.No MX/a/2008/014959 Applicant ELI LILLY AND COMPANY. Inventor Tianwei Ma
Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
4.MX/a/2008/015045DECODING OF PREDICTIVELY CODED DATA USING BUFFER ADAPTATION
MX - 12.02.2009
Int.Class G10L 19/04
GPHYSICS
10MUSICAL INSTRUMENTS; ACOUSTICS
LSPEECH ANALYSIS TECHNIQUES OR SPEECH SYNTHESIS; SPEECH RECOGNITION; SPEECH OR VOICE PROCESSING TECHNIQUES; SPEECH OR AUDIO CODING OR DECODING
19Speech or audio signal analysis-synthesis techniques for redundancy reduction, e.g. in vocoders; Coding or decoding of speech or audio signals, using source filter models or psychoacoustic analysis
04using predictive techniques
 Appl.No MX/a/2008/015045 Applicant NOKIA CORPORATION Inventor JUHA OJANPERA
A decoder (e.g., an AAC-LTP decoder) receives a stream containing coded audio data and prediction data. The coded data is upsampled or downsampled during decoding. Portions of the decoded data are stored in a buffer for use in decoding subsequent coded data. The buffer into which the decoded data is placed has different dimensions than a buffer used in a coder when generating the coded data. A portion of the data in the decoder buffer is identified and modified with interleaved zero values so as to correspond to the dimensions of the prediction coding buffer in the coder.
5.MX/a/2008/015268BASEPAN ASSEMBLY FOR AN ELECTRICAL PANEL
MX - 12.02.2009
Int.Class H02B 1/056
HELECTRICITY
02GENERATION, CONVERSION, OR DISTRIBUTION OF ELECTRIC POWER
BBOARDS, SUBSTATIONS OR SWITCHING ARRANGEMENTS FOR THE SUPPLY OR DISTRIBUTION OF ELECTRIC POWER
1Frameworks, boards, panels, desks, casings; Details of substations or switching arrangements
015Boards, panels, desks; Parts thereof or accessories therefor
04Mounting thereon of switches or of other devices in general, the switch or device having, or being without, casing
056Mounting on plugboards
 Appl.No MX/a/2008/015268 Applicant SIEMENS ENERGY&AUTOMATION, INC.* Inventor Joseph Scott Dixon
A system comprising:a basepan assembly for an electrical panel, said basepan assembly made up of an interconnectable plurality of pieces, a first piece from said plurality of pieces comprising:an inserter;and a reciever adapted to slidably recieve an inserter of a second piece from said plurality of pieces and, for each of three mutually perpendicular axes, to releasably restrain said second piece from moving relative to said first piece in at least one direction parallel to said axis;in an operative embodiment, said basepan assembly adapted to:retain a plurality of bus bars to said electrical panel;mutually align said plurality of bus bars;restrain motion of said plurality of bus bars in said one or more directions parallel to any of said three mutually perpendicular axes;and mutually electrically insulate said pluralityof bus bars.
6.MX/a/2008/015303USE OF STARCH WITH SYNTHETIC METAL SILICATES FOR IMPROVING A PAPERMAKING PROCESS
MX - 12.02.2009
Int.Class D21H 17/28
DTEXTILES; PAPER
21PAPER-MAKING; PRODUCTION OF CELLULOSE
HPULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C, D21D84; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G97; PAPER NOT OTHERWISE PROVIDED FOR
17Non-fibrous material added to the pulp, characterised by its constitution; Paper-impregnating material characterised by its constitution
20Macromolecular organic compounds
21of natural origin; Derivatives thereof
24Polysaccharides
28Starch
 Appl.No MX/a/2008/015303 Applicant NALCO COMPANY Inventor JANE B. WONG SHING
The invention discloses a paper or paperboard produced from a slurry comprising cellulose fibers and an effective amount of SMS. In addition, a method for increasing retention and dewatering during the papermaking process is also disclosed. The method involves the addition of an effective amount of SMS to said papermaking process. The invention also discloses a method for increasing retention and drainage in a papermaking process comprising the steps of:adding both an effective amount of starch and an effective amount of SMS to a slurry of said papermaking process, wherein said starch is selected from the group consisting of:tapioca starch;potato starch;corn starch;waxy maize starch;rice starch;and wheat starch. Moreover, the invention comprises a method for increasing retention and drainage in a papermaking process comprising the steps of:adding both an effective amount of modified starch and an effective amount of SMS to a slurry of said papermaking process.
7.MX/a/2008/0153084-AMINO-PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM
MX - 12.02.2009
Int.Class A61K 31/4985
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
 Appl.No MX/a/2008/015308 Applicant ELBION GMBH Inventor Norbert HÖFGEN
The invention relates to 4-amino-pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 10 activity in the central nervous system. More particularly, the invention relates to the treatment of neurologic and psychiatric disorders, for example psychosis and disorders comprising cognitive deficits as symptoms.
8.MX/a/2008/015328BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXYTRYTAMINE-6 LIGANDS
MX - 12.02.2009
Int.Class A61K 31/423
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42Oxazoles
423condensed with carbocyclic rings
 Appl.No MX/a/2008/015328 Applicant WYETH.* Inventor HASSAN MAHMOUD ELOKDAH
The present invention provides a compound of Formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
9.MX/a/2008/015350INJECTION DEVICE WITH SYRINGE CARRIER ENGAGEMENT WITH CAP
MX - 12.02.2009
Int.Class A61M 5/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
5Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
178Syringes
20Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
 Appl.No MX/a/2008/015350 Applicant CILAG GMBH INTERNATIONAL Inventor BRADY, Matthew James
An injection device (110) is described having a housing (112) that receives a syringe (114) having a needle (118), wherein the syringe is supported in a syringe carrier (150). The injection device (110) has a removable cap (190). The syringe (114) and syringe carrier (150) are biased by a return spring (126) from an extended position in which the needle (118) extends from the housing (112) through an exit aperture (128) to a retracted position in which it does not. The syringe carrier (150) abuts a surface inside the removable cap (190) which prevents forward movement of the syringe carrier (150) when the cap is in place. The injection device is less prone to failure than prior art devices and is safer should failure occur.
10.MX/a/2008/015395USE OF CD83 IN COMBINATION THERAPIES
MX - 12.02.2009
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
 Appl.No MX/a/2008/015395 Applicant ARGOS THERAPEUTICS, INC. Inventor CHARLES NICOLETTE
The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.
# -